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Abstract The capsid (CA) domain of retroviral Gag proteins 
posseses one subdomain, the major homology region (MHR), 
which is conserved among nearly all avian and mammalian retro- 
viruses. While it is known that the mutagenesis of residues in the 
MHR will impair virus infectivity, the precise structure and func- 
tion of the MHR is not known. In order to obtain further informa- 
tion on the MHR, we have examined the structure of a synthetic 
peptide encompassing the MHR of human immunodeficiency 
virus type I (HIV-l) CA protein. Multiple sequence alignment 
and secondary structure prediction indicate that the peptide could 
form 50% o-helix and 10% P-sheet. In addition, circular di- 
chroism studies indicate that, in the presence of 50% 
trifluoroethanol (TFE), the peptide adopts an cy-helical structure 
over half of its length. Further analysis by proton nuclear mag- 
netic resonance spectroscopy suggests that the C-terminal portion 
of the MHR forms a helix in aqueous solution. Upon the addition 
of TFE, the position of the helix remains nearly constant, but the 
magnitude of the changes in H, chemical shifts of the residues 
indicate a more stable helix. These results suggest that a helical 
C-terminus of retroviral MHRs may be integral to the function 
of this region. 
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1. Introduction 
The structural proteins of human immunodeficiency virus 
type 1 (HIV-l) are translated as a polyprotein precursor 
(Pr55XUR) [1,2] from the gag gene mRNA, which also is the 
full-length HIV-I viral RNA. During or after virus assembly, 
virus protease-catalyzed processing of Pr55X0g yields the viral 
proteins matrix (MA), capsid (CA) and nucleocapsid (NC), and 
p6 [3]. Of these proteins, structures have been provided for MA 
[4,5], which interacts with the viral membrane [6] and the viral 
envelope protein [7,8]; and for the NC protein [9,10], which 
helps encapsulate the viral RNA during virus assembly [l 11. To 
date, no structure determination has been reported for the 
HIV-1 p6 protein, which facilitates particle budding [ 121; or for 
CA, which is required for the formation of the capsid in imma- 
ture and mature virus particles. 
Interestingly, retrovirus CA primary sequences are poorly 
conserved, with the exception of a sequence termed the major 
homology region (MHR) (Fig. 1) [l]. The MHR exists, invari- 
ant in its location, in the capsid proteins of all avian and mam- 
malian retroviruses for which the gag sequence is known, with 
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the exception of spumaretroviruses [13]. Given the sequence 
conservation of the MHR, it seems likely that this CA subdo- 
main plays a conserved role in virus replication, either via an 
interaction with cellular factors or another viral component. 
However, molecular genetic studies have only hinted at the 
functional significance of the MHR. Some mutations, for in- 
stance, alteration of MHR residues glutamine- and gluta- 
mate-159, blocked virus particle assembly [13]. Other muta- 
tions, including a deletion of HIV-l MHR residues, blocked 
virus replication and reduced virus assembly [ 13,141. However, 
mutations, such as an arginine to alanine substation at residue- 
167, while blocking virus replication, had no apparent effect on 
the efficiency of virus particle assembly [ 131. Similarly, cysteine 
substitutions for C-terminal MHR residues permit efficient 
virus particle assembly, RNA encapsulation and Pr55”“” pro- 
tein processing, but block virus infectivity (McDermott, Far- 
rell, Zhang and Barklis, unpubl. obs.). Thus, the MHR may 
effect an early stage of virus particle assembly, a later post- 
assembly stage of the virus life cycle, or multiple stages. 
In order to help elucidate the role of retroviral MHRs and 
capsid proteins, we wished to determine the secondary struc- 
ture of the HIV-l MHR. To date, the only information regard- 
ing the MHR structure has been based on a sequence compar- 
ison of retroviral CA and picornaviral VP2 proteins, suggesting 
P-strand stretching from tyrosine-164 to threonine-171 [ 151. In 
contrast, we present here spectroscopic evidence for the exis- 
tence of an a-helix that extends from phenylalanine-I 61 to 
arginine-176 in an HIV-l CA protein MHR peptide analog. 
Our results suggest that the C-terminal portion of the MHR 
may form an amphipathic helix which may interact with cellular 
and/or viral components as an essential step in the HIV life 
cycle. 
2. Materials and methods 
2.1. Peptide synthesis andpurtjication 
The 31-residue MHR containing peptide (Fig. I) was obtained from 
a commercial supplier (Peptide Express, Colorado State University, 
Fort Collins. CO). The peptide was svnthesized with a cvsteine residue 
located at the N-terminus’for use in complimentary studies. The crude 
peptide was purified by preparative reverse-phase HPLC and its iden- 
tity confirmed by mass spectrometry. 
2.2. Secondary structure prediction 
Secondary structure predictions according to Rost and Sander [16 
181 were obtained interactively from the PredictProtein server at EMBL 
(http://www.embl-heidlberg.delpredictproteinlphd_pred.html, on the 
World Wide Web). 
2.3. Circular dichroism spectroscopy 
Aliquots of an aqueous 2 mg/ml stock peptide solution were diluted 
with appropriate amounts of water and TFE to prepare samples con- 
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taming 1 .O mg/ml peptide and 0% or 50% TFE (wt/wt). The CD spec- 
trum for each sample was measured over a wavelength range of 180-260 
nm on a JASCO J-500 CD Spectrometer (Easton, MD) using 4 scans 
per sample with a scan rate of 10 nm/min at 25°C. The resulting spectra 
were analysed for secondary structure using the program VARSLCl 
[19,20] in which the basis set included 33 proteins. 
2.4. Nuclear magnetic resonance spectroscopy 
NMR sample concentrations were 557 mM peptide and 0% or 50% 
TFE-dZ (ISOTEC, Miamisburg, OH) (wt/wt) in aqueous solutions con- 
taining 10% D,O. The pH was adjusted to 3.1 to minimize H, peak 
broadening due to exchange with the solvent [21]. All spectra were 
referenced to the solvent (H,O) peak at 4.76 ppm. A crystal of dithionite 
was added to each sample to prohibit disulfide bond formation between 
peptide molecules. 
NMR spectra were acquired at 298 K on a Bruker AMX-400 spec- 
trometer, using a dedicated 5-mm proton probe, locked to the deu- 
terium resonance of the solvent and without spinning. In order to assign 
the proton chemical shifts, nuclear Overhauser spectroscopy (NOESY) 
[22], double-quantum-filtered J-correlated spectroscopy (DQF-COSY) 
[23] and total correlation J-spectroscopy (TOCSY) [24] spectra were 
recorded in the phase-sensitive mode by the time proportional phase 
incrementation method (TPPI) [25]. TOCSY spectra were recorded at 
mixing times of 53 and 90 ms to aid the assignment of the longer 
side-chain resonances. NOESY spectra were acquired at mixing times 
of 100, 150 and 300 ms, with 512 t, values, and 2048 data points in tZ. 
Data were processed on an SGI Indy (Silicon Graphics Computer 
Systems, Mountain View, CA) workstation using FELIX (Biosym 
Technologies, San Diego, CA). Solvent supression was achieved by 
presaturation during the relaxation delay. 2D spectra were zero-filled 
in both dimensions to give 1024 x 1024 TOCSY and COSY real matri- 
ces and 2048 x 2048 NOESY real matrices and baseline corrections 
were applied as needed. Spectra were assigned much as in Wtithrich 
WI. 
Fig. 2. Secondary structure of the MHR by various methods. (A) 
Results from PredictProtein secondary structure prediction indicating 
the probability of each residue being part of an a-helix. (B) Difference 
between random coil [29] and observed H, chemical shifts of the HIV-l 
MHR-containing peptide in 0% TFE (circles) and 50% TFE (boxes). 
(C) Chemical shift index of a-protons of the peptide in 0% TFE. (D) 
Chemical shift index of a-protons of the peptide in 50% TFE. 
3. Results and discussion 
Fig. 1. Primary structure of the MHR. (A) Sequence of the studied 
peptide analog of the CA MHR (HIV-l peptide) and results of 
PredictProtein secondary structure prediction of the HIV-1 peptide. 
The peptide numbering scheme is indicated below the sequence, while 
the corresponding CA sequence numbering is shown above. (H) a-helix; 
(E) B-strand. (B) Alignment of CA sequences of different retroviruses 
in the major homology region (MHR). The absolutely conserved resi- 
dues occur at positions 155, 159 and 167, while an aromatic residue 
consistently occurs at position 164. HIV-2, human immunodeficiency 
virus type 1; SIV (TYO-1) and SIV (K6W), simian immunodeficiency 
virus isolates TYO-1 and K6W, MPMV, Mason-Pfizer monkey virus; 
EIAV, equine infectious anemia virus; HTLV-I and HTLV-II, human 
T-cell leukemia virus types I and II; MO-MLV, Molony murine leuke- 
mia virus; FLV and BLV, feline and bovine leukemia viruses; MMTV, 
mouse mammary tumor virus; RSV, Rous sarcoma virus. 
l- 
The sequence of the peptide as shown in Fig. 1 was submitted 
to the PredictProtein server for multiple sequence alignment 
and secondary structure prediction. According to the predic- 
tion, residues isoleucine-3 through aspartate-5 might adopt a 
P-strand structure while residues phenylalanine-14 through glu- 
tamate-28 would form an cl-helix (Fig. 1). The percentage prob- 
ability of each residue being in an a-helix, as determined by the 
prediction, is shown in Fig. 2A. This result is in disagreement 
with prior predictions as to the tertiary structure of HIV-l CA 
via sequence alignment with picornaviral proteins [15], in which 
it was suggested that residues tyrosine- 17 through threonine-24 
of the peptide analog form a B-strand in the CA protein. 
We also examined the CD spectrum of the MHR peptide in 
aqueous and TFE containing solutions. As indicated by the CD 
spectrum in Fig. 3, the peptide adopts very little secondary 
structure in aqueous solution. However, in aqueous solution 
containing 50% TFE an intense positive band at 193 nm and 
strong negative bands at 208 and 218-222 nm were observed, 
indicating the presence of a-helix. TFE allows for the stabiliza- 
tion of intramolecular hydrogen bonds, such as those between 
amide protons and carbonyl oxygens in u,-helices. Hydrogen 
bonding to the solvent is reduced because TFE is a weaker base 
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Fig. 3. CD spectra of the HIV-l MHR containing peptide. The solid 
line is for aqueous solution only and the dotted line is for aqueous 
solution containing 50% TFE. 
than water and as a consequence intramolecular hydrogen 
bonds are favored [26]. The relative amounts of secondary 
structure were estimated using the program VARSLCl [19,20]. 
By this calculation, the helicity increased to 49% in 50% TFE 
from 5% in the absence of TFE. The absence of substantial 
helicity at 0% TFE could be due to a distortion of the ideal 
a-helical geometry caused by motion at the ends of the peptide, 
leading to a diminished CD signal [27]. The calculated amounts 
of/?-sheet were 19% and 10% for the 0% and 50% TFE solu- 
Table 1 
Proton chemical shifts of HIV-l peptide in 50% TFE” 
No. Residue NH Ha HB HY Other 
1 Cysb 
2 Ser 
3 Ile 
4 Leu 
5 Asp 
6 Ile 
7 Arg 
8 Gln 
9 Gly 
10 Pro 
11 LYS 
12 Glud 
13 Pro 
14 Phe 
15 Arg 
16 Asp 
17 TYr 
I8 Val 
19 Asp 
20 Arg 
21 Phe 
22 TYr 
23 LYS 
24 Thr 
25 Leu 
26 Arg 
27 Ala 
28 Glu 
29 Gln 
30 Ala 
31 Ser 
8.82 
8.33 
7.71 
7.85 
7.60 
8.05 
7.96 
7.90 
8.41 
7.50 
8.05 
8.29 
7.77 
8.09 
8.25 
7.83 
8.41 
8.54 
8.24 
7.87 
7.98 
8.05 
7.82 
8.05 
7.94 
7.80 
7.78 
tions, respectively. However, p-sheet formation is unlikely in 
such a short peptide and so CD signals corresponding to /?- 
sheet-like conformations may have been due to chance orienta- 
tion of amide bonds. 
To test our interpretation of the HIV-l MHR peptide CD 
spectra, the peptide was subjected to analysis by NMR. ‘H 
NMR assignments were carried out using the general strategy 
of Wiithrich [21]. Essentially complete amino acid spin systems 
were identified from the 2D TOCSY and DQF-COSY spectra. 
A representative plot of the fingerprint region of the DQF- 
COSY spectrum is shown in Fig. 4. The cross-peaks corre- 
sponding to 3JnNU couplings were identified for all residues 
except glutamate-12, where we believe the major complications 
to finding the resonances from this residue arise from spectral 
overlap with signals from other protons. We note, however, 
that this residue is not in the region identified as helical below. 
Sequence specific assignments were then determined from 
short-range NOES between H,, H, and HB of residue i and H, 
of residue i + 1. The assignments of the peptide in 50% TFE are 
summarized in Table 1, with the H, resonances of the peptide 
in 0% TFE also indicated. 
H, chemical shifts have been shown to be dependent on the 
type of secondary structure of which the residue is a part [28]. 
Protons with upfield shifts relative to random coil values tend 
to occur in helices while those with downfield shifts occur in 
p-structures. An empirical chemical shift index (CSI) technique 
for fast approximations of secondary structure has been devel- 
4.28 3.03. 3.11 
4.69 (4.57)’ 4.02, 3.85 
4.09 (4.17) 1.86 
4.16 (4.30) 1.59, 1.59 
4.58 (4.69) 2.85, 2.85 
4.01 (4.13) 1.97 
4.19 (4.31) 1.83, 1.88 
4.41 (4.36) 2.02, 2.02 
4.07, 4.07 (4.08, 4.08) 
4.49 (4.44) 1.93, 2.30 
4.36 (4.53) 1.79, 1.79 
4.40 (4.36) 1.80, 2.26 
4.49 (4.53) 3.15, 3.15 
3.91 (4.15) 1.87, 1.87 
4.43 (4.56) 2.77, 2.77 
4.18 (4.46) 3.12, 3.12 
3.53 (3.92) 2.00 
4.50 (4.57) 2.81, 2.96 
3.97 (4.11) 1.85, 1.85 
4.15 (4.52) 2.89, 3.14 
4.05 (4.42) 3.10, 3.10 
3.84 (4.20) 1.86, 1.92 
3.86 (4.24) 4.25 
3.90 (4.26) 1.43, 1.43 
3.95 (4.23) 1.74, 1.74 
4.12 (4.23) 1.48 
4.14 (4.23) 2.15, 2.15 
4.19 (4.37) 2.06, 2.14 
4.16 (4.39) 1.41 
4.43 (4.41) 3.94, 3.94 
1.25, 1.46 yCH, 0.91 SCH, 0.86 
1.57 6CH, 0.81, 0.88 
1.21, 1.50 
1.65, 1.72 
2.18, 2.38 
yCH, 0.90 JCH, 0.83 
SCH 3.15, 3.15 &NH 7.28 
2.01, 2.01 
1.48, 1.48 
1.97, 1.97 
1.64, 1.71 
6CH 3.60, 3.60 
6CH 1.69, 1.69 &CH 3.01, 3.01 
6CH 3.56, 3.69 
6CH 7.15 &CH 7.25 
SCH 3.20, 3.20 &NH 7.21 
6CH 7.01 &CH 6.73 
0.83, 0.94 
1.51, 1.65 
1.41, 1.41 
1.15 
1.43 
1.44, 1.53 
6CH 3.10, 3.10 &NH 7.83 
6CH 6.94 .sCH 7.17 
XH 7.13 eCH 6.79 
6CH 1.65, 1.65 &CH 2.95, 2.95 
6CH 0.70, 0.70 
6CH 3.05, 3.05 &CH 7.12 
2.46, 2.58 
2.39, 2.47 
“The chemical shifts are given in ppm and are referenced to H,O (4.76 ppm at 298 K). 
bNH resonance not found due to exchange with solvent. 
‘H, values in parentheses are for 0% TFE as the solvent. 
“Glu 12 resonances not identified due to extensive overlap. 
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Fig. 4. Part of a DQF-COSY spectrum of the MHR peptide. The 
peptide was 5 mM, in aqueous 50% TFE (by weight) solution. at pH 
3.1 and 298K. Cross-peaks for NH to H, correlations are labeled for 
all residues except those of cysteine-1, glutamate-12, proline- and 
proline-13. 
oped in which each H, is assigned a value of 1 if it has been 
downfield shifted by ~0.1 ppm, a value of 0 if the shift is kO.1 
ppm or a value of -1 if it has been upfield shifted by >O. 1 ppm 
[29]. Four consecutive H, values with values of -1 are in a- 
helices while three consecutive values of 1 constitute p-struc- 
tures. 
The chemical shift differences between the H,s of the peptide 
in both 0% and 50% TFE and random coil values are shown 
in Fig. 2B. As shown, the H, chemical shift differences are small 
on the N-terminal part of the peptide and are similar for both 
concentrations of TFE, suggesting that this portion of the pep- 
tide is disordered. In contrast, upfield chemical shift differences 
are evident in the C-terminal portion of the peptide, from phen- 
ylalanine-14 to the C-terminus in the absense of TFE. Further- 
more, the magnitude of the chemical shift differences increased 
significatly when in 50% TFE solution. Chemical shift index 
plots of the peptide in both TFE concentrations are shown in 
Fig. 2C,D. This analysis is indicative of an a-helix extending 
between residues 14-27 in 0% TFE and between residues 14- 30 
in 50% TFE. The magnitude of the chemical shift difference 
increased when TFE is present in solution in the a-helical por- 
tion of the peptide, suggesting that a more stable helix forms. 
doN(l.i+l) _ I I -_- 
dNN(i.1’1, - 
dgN(i,i+l) - - - - - - - - 
dNN(i,i+f, - -- - 
doN(i,i+3) - x_- =- x m 
daN(i,i+4) -- 
dog(i,i+X) - 
-- 
- 
Fig. 5. Summary of the observed short- and medium-range NOES for 
the MHR containing peptide in 50% TFE. The thick. medium and thin 
lines correspond to strong, medium and weak NOES, respectively. 
Fig. 6. Helix-wheel model of the amphipathic helix formed by residues 
14 through 26 of the HIV-l MHR peptide. Residues F14, Y17, Vl8, 
F21, Y22 and L25 form a hydrophobic face while residues R15, D16, 
D19, R20, K23 and R26 occupy a hydrophilic side of the helix. 
The chemical index data suggests that the peptide is 52% a-helix 
in 50% TFE, but gives no evidence for the presence ofp-strand, 
all of which is in agreement with our CD and PredictProtein 
analyses. 
The presence of medium-range NOES, such as d,,(i,i + 2) 
d,,(i,i + 3), d,,(i,i + 4) and d,(i,i + 3) are further evidence 
of helical regions [12]. In addition to sequential NOES of the 
types d,,(i,i + l), d,,(i,i + 1) and dBN(i,i + l), observed me- 
dium-range NOES are summarized in Fig. 5. Spectral overlap 
prohibited the observation of several NOES, nevertheless the 
pattern of NOES shown in Fig. 5 serves as strong evidence for 
the presence of an a-helix that stretches from about residue 14 
to residue 29. 
Our NMR data is, therefore, in agreement with the CD 
results, suggesting that TFE stabilizes MHR helix formation. 
Furthermore, our assignment of the C-terminal portion of the 
MHR peptide as helical based on NMR chemical shift differ- 
ences is in remarkable agreement with PredictProtein second- 
ary structure predictions. While we do not yet have a complete 
structure determination for the HIV-l MHR, it is noteworthy 
that peptide residues 14-26 can be modeled to form an am- 
phipathic a-helix. By such a model (Fig. 6), peptide residues 
phenylalanine- 14, tyrosine- 17, valine- 18, phenylalanine-21, ty- 
rosine-22 and leucine-25 would form a hydrophobic helical 
face, while residues arginine- 15, aspartate- 16, aspartate- 19, 
arginine-20, lysine-23 and arginine-26 would occupy the polar 
side of the helix. It is intriguing to speculate that such an 
amphipathic helix on one Gag protein monomer may interact 
with another helix on an adjacent monomer. Alternatively, an 
amphipathic MHR helix may bind to other viral components 
or cellular factors to facilitate virus assembly and/or infection. 
Such possibilities currently are under investigation. 
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